New framework enhances genetic prediction of drug response and side effects

A UCLA study has outlined a new framework that researchers say would improve predictive power of genetics to determine how well a patient would respond to commonly prescribed medications as well as the severity of any side effects.

Autoimmune brain disease startup Arialys gets new leader; Intellia, Arvinas appoint CFOs

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 29, 2024

2025 could bring some sunshine for health tech startups

After a tough few years, healthcare startups are entering 2025 with cautious optimism. Twelve months ago, early-stage startups faced a funding cliff … Sign up

December 20, 2024

VORANIGO approved by Health Canada for IDH-mutant glioma

VORANIGO, a dual inhibitor of mutant IDH1 and IDH2 enzymes, is designed to penetrate the blood-brain barrier. Credit: CNW Group/Servier Canada. Servier Canada has announced

October 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.